Nuveen Mortgage and Income Fund
Change company Symbol lookup
Select an option...
JLS Nuveen Mortgage and Income Fund
JNJ Johnson & Johnson
QIAN Qiansui International Group Co Ltd
BV Brightview Holdings Inc
PFE Pfizer Inc
MP Mp Materials Corp
WFG West Fraser Timber Co Ltd
MDT Medtronic PLC
ATMR^ Altimar Acquisition Corp II
AEG Aegon NV
Go

Company profile

Nuveen Mortgage and Income Fund (the Fund), formerly Nuveen Mortgage Opportunity Term Fund, is a non-diversified, closed-end management investment company. The Fund's investment objective is to generate attractive total returns through opportunistic investments in mortgage-backed security (MBS). It seeks to achieve its investment objective by investing primarily in non-agency residential MBS and commercial MBS. The Fund may also invest up to 20% of its managed assets in other permitted investments, including cash and cash equivalents, the United States treasury securities, non-mortgage related asset-backed securities, inverse floating rate securities, municipal securities, interest rate futures, interest rate swaps and swaptions, non-MBS credit default swaps and other synthetic mortgage-related exposure, including equity investments in mortgage real estate investment trusts (REITs). The Fund's investment advisor is Nuveen Fund Advisors, LLC.

Closing Price
$21.02
Day's Change
-0.0666 (-0.32%)
Bid
--
Ask
--
B/A Size
--
Day's High
21.10
Day's Low
21.01
Volume
(Heavy Day)
Volume:
13,970

10-day average volume:
8,258
13,970

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of DOX, CAN and ACAD

2:46 pm ET May 4, 2021 (Accesswire) Print

NEW YORK, NY / ACCESSWIRE / May 4, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Amdocs Limited (NASDAQ:DOX)

Class Period: December 13, 2016 - March 30, 2021

Lead Plaintiff Deadline: June 8, 2021

The complaint alleges that throughout the class period Amdocs Limited made materially false and/or misleading statements and/or failed to disclose that: (i) Amdocs overstated its profits, cash, and liquidity, while understating its debt; (ii) Amdocs concealed its large borrowing; (iii) while Amdocs' reported results showed that its North American business was stable, that business was actually deteriorating annually, in part because the Company was losing AT&T as a customer; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in DOX: http://www.kleinstocklaw.com/pslra-1/amdocs-limited-loss-submission-form?id=15464&from=1

Canaan Inc. (NASDAQ:CAN)

Class Period: February 10, 2021 - April 9, 2021

Lead Plaintiff Deadline: June 14, 2021

According to the complaint, Canaan Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: they concealed that due to ongoing supply chain disruptions and the introduction of the Company's next-generation A12 series bitcoin mining machines - which had cannibalized sales of the older product offerings - Canaan's 4Q20 sales had declined more than 93% year-over-year compared to its fourth quarter fiscal year 2019 ("4Q19") sales and more than 93% quarter-over-quarter compared to its third quarter FY20 ("3Q20") sales.

Learn about your recoverable losses in CAN: http://www.kleinstocklaw.com/pslra-1/canaan-inc-loss-submission-form-2?id=15464&from=1

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD)

Class Period: June 15, 2020 - April 4, 2021

Lead Plaintiff Deadline: June 18, 2021

The ACAD lawsuit alleges Acadia Pharmaceuticals Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (i) the materials submitted in support of the pimavanserin sNDA contained statistical and design deficiencies; (ii) accordingly, the pimavanserin sNDA lacked the evidentiary support that the Company had led investors to believe it possessed; (iii) the FDA was unlikely to approve the pimavanserin sNDA in its present form; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in ACAD: http://www.kleinstocklaw.com/pslra-1/acadia-pharmaceuticals-inc-loss-submission-form?id=15464&from=1

Image: https://www.accesswire.com/users/newswire/images/644459/image-20210504142258-1.png

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

J. Klein, Esq.

Empire State Building

350 Fifth Avenue

59th Floor

New York, NY 10118

jk@kleinstocklaw.com

Telephone: (212) 616-4899

Fax: (347) 558-9665

www.kleinstocklaw.com

SOURCE: The Klein Law Firm

View source version on accesswire.com:

https://www.accesswire.com/644459/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-DOX-CAN-and-ACAD

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.